Dr. Schmitt received his doctoral degree and completed a fellowship at the University of Akron, Ohio. His clinical interests include biostatistics, dementia, and HIV. Schmitt is the Mary Carter Award recipient for his work with patients with Down syndrome and neurodegenerative disease, and is a nationally and internationally renowned expert on neurodegenerative conditions including Alzheimer’s disease. He is a principal investigator and consultant on numerous grants from the NIH and other federal and state funding mechanisms. He has over 30 years of clinical experience in neurocognition.

Dr. Lott is a child neurologist at the University of California, Irvine and CHOC Children’s Hospital. He graduated from Ohio State University College of Medicine and received his training in pediatrics, neurology, and child neurology through Massachusetts General Hospital, Harvard Medical School. He served as a Clinical Research Associate at the National Institute of Child Health and Human Development. He was on the faculty at Harvard Medical School as Clinical Director of the Eunice Kennedy Schriver Center from 1974-1983.

In 1983, Dr. Lott was recruited to the University of California, Irvine where he has been a tenured professor. In 2012, he became Emeritus Professor. He served as Director for the Division of Child Neurology from 1983-2011 and Chairman of the Department of Pediatrics from 1990-2000. He directed the ACGME Child Neurology Residency Program at UCI from 1983-2011. In May 2000, he assumed the title of Associate Dean, Clinical Neuroscience for UCI’s School of Medicine. Currently has directed the Telemedicine program for the UCI Health Sciences. Dr. Lott has been a standing member of the Developmental Biology Study Section at NICHD and has served on many ad-hoc NIH committees.

Dr. Lott’s research interest is focused on development and aging in Down syndrome. He received two national awards for his research and has been commended by the California State Senate for his work on behalf of individuals with intellectual disabilities. In 2016, Dr. Lott received the annual research award from UCI’s Alzheimer’s disease program. He served as Chairman of the Scientific Advisory Board of the National Down Syndrome Society and is a Board member of the Down Syndrome Association of Orange County. Dr. Lott’s research has been supported by the National Institutes of Health, Alzheimer’s Association, and the State of California. Dr. Lott has been cited among the “best doctors” for over 20 years.

Dr. Head received a master’s in psychology and a PhD in Neuroscience from the University of Toronto, Canada. She received postdoctoral training at the Institute for Brain Aging & Dementia at the University of California, Irvine. Dr. Head moved to the University of Kentucky in January of 2009 and was a Professor and Associate Director of Education at the Sanders-Brown Center on Aging. Now at the University of California at Irvine, she is a Professor and Vice Chair for Research in the Department of Pathology & Laboratory Medicine. Dr. Head has published over 150 peer reviewed papers, over 30 review papers and book chapters. Dr. Head has dedicated over 20 years to the study of aging and Alzheimer’s disease with a focus on people with Down syndrome.

Dr. Karlsson has board certifications in both general psychiatry and child and adolescent psychiatry. Her clinical and research focus is in the treatment of individuals with autism, developmental disorders and other neuropsychiatric conditions throughout the lifespan. She is the founder and director of the Down Syndrome Psychiatric Specialty Clinic at the IU Neurosciences Center, serving both children and adults, with a specific focus on regression and catatonia in Down Syndrome.

Dr. Apostolova’s research focuses on the early symptomatic and presymptomatic stages of Alzheimer’s disease and on the development and validation of sensitive imaging and genetic biomarkers for Alzheimer’s disease and other dementing disorders. Dr. Apostolova is the Principal Investigator of the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) – a multisite national consortium focused on early-onset AD, a rare form of Alzheimer’s that affects middle-aged individuals.

Dr. Lerner is a graduate of the New York State College of Agriculture and Life Science at Cornell University in Ithaca, NY and Cornell University Medical School in New York City. He completed an internship in Internal Medicine at Lenox Hill Hospital in New York City. He then completed a Residency in Neurology (1988-1991) and Fellowship in Behavioral Neurology at University Hospitals and Case Western Reserve University (1991-1993). He is currently Director of the Brain Health and Memory Center at the Neurological Institute of University Hospitals Case Medical Center. He holds the Neurological Institute endowed chair in memory and cognition, and is Professor of Neurology, Case Western Reserve University School of Medicine. He is one of the founders of the Cleveland Brain Health Initiative and a member of the executive committee.

Dr. Lerner is a Behavioral Neurologist with almost three decades experience in treating memory disorders such as Alzheimer’s disease, aging in Down Syndrome and related disorders. He is active in conducting clinical research studies focusing on new diagnostics and treatments for Alzheimer’s disease, and other dementias. Current studies include new dementia prevention studies both by risk factor reduction and use of experimental medications. He represents CWRU on the steering committees of the Alzheimer’s Clinical Trials Consortium and the Alzheimer’s Disease Neuroimaging initiative.  The clinical research site at University Hospitals is actively working with the Global Alzheimer’s Platform to promote Brain Health in diverse communities, and accelerate clinical trials in Alzheimer’s disease. His clinical practice is focused on diagnosis and treatment of dementia and behavioral disorders. He has written published extensively in the areas of general Neurology, Alzheimer’s disease and other dementias.